explore -WSS

explore

author：hotspot 2025-10-01 20:15:27 - browse：7

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Venture capital firm's plans to take over Akron hospital face hurdles

WSS

It's time to retire 'poor historian' from clinicians' vocabularies

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Solving academic medical centers' existential crisis

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Tori Bowie and the unacceptable rates of Black maternal death

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Cancer drug shortages should be causing more outrage

Venture capitalist Bob Kocher on the state of digital health

Tori Bowie and the unacceptable rates of Black maternal death

Venture capital firm's plans to take over Akron hospital face hurdles

As demand for Covid shots wanes, Moderna seeks its next success

FTC sues over Novant Health acquisition of two N.C. hospitals

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

With measles on the rise, a personal story of a devastating disease

leisure time

Health Care Service Corp to buy Cigna Medicare Advantage plans

Venture capital firm's plans to take over Akron hospital face hurdles

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Why you shouldn’t ask, “What country has the best health care?”

HIV vaccine remains elusive. Immunologists keep trying new ideas

Addiction experts warn against a second 'war on drugs'

hotspot

leisure time

entertainment

knowledge